APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liver Diseases Therapeutics Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liver Diseases Therapeutics Drugs Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchLiver Diseases Therapeutics Drugs Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Liver Diseases Therapeutics Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Liver Diseases Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liver Diseases Therapeutics Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Liver Diseases Therapeutics Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Liver Diseases Therapeutics Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liver Diseases Therapeutics Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liver Diseases Therapeutics Drugs market include Achillion Pharmaceuticals, Angion Biomedica, F. Hoffmann-La Roche, Gilead Sciences, LG Life Sciences, Phenex Pharmaceuticals, ProMetic Life Sciences, Raptor Pharmaceuticals and Verva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liver Diseases Therapeutics Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liver Diseases Therapeutics Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liver Diseases Therapeutics Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liver Diseases Therapeutics Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Liver Diseases Therapeutics Drugs Segment by Company

Achillion Pharmaceuticals

Angion Biomedica

F. Hoffmann-La Roche

Gilead Sciences

LG Life Sciences

Phenex Pharmaceuticals

ProMetic Life Sciences

Raptor Pharmaceuticals

Verva Pharmaceuticals

AbbVie

Bayer

GlaxoSmithKline

Merck

Johnson & Johnson

Shenzhen Kangtai Biological Products

Liver Diseases Therapeutics Drugs Segment by Type

Oral Liver Diseases Therapeutics Drugs

Injection Liver Diseases Therapeutics Drugs

Liver Diseases Therapeutics Drugs Segment by Application

Hospitals

Clinics

Other

Liver Diseases Therapeutics Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Liver Diseases Therapeutics Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liver Diseases Therapeutics Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liver Diseases Therapeutics Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Liver Diseases Therapeutics Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Diseases Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liver Diseases Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Diseases Therapeutics Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liver Diseases Therapeutics Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liver Diseases Therapeutics Drugs industry.

Chapter 3: Detailed analysis of Liver Diseases Therapeutics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liver Diseases Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liver Diseases Therapeutics Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liver Diseases Therapeutics Drugs Industry Trends Table 2. Liver Diseases Therapeutics Drugs Industry Drivers Table 3. Liver Diseases Therapeutics Drugs Industry Opportunities and Challenges Table 4. Liver Diseases Therapeutics Drugs Industry Restraints Table 5. Global Liver Diseases Therapeutics Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liver Diseases Therapeutics Drugs Revenue Share by Company (2021-2026) Table 7. Global Liver Diseases Therapeutics Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Liver Diseases Therapeutics Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Liver Diseases Therapeutics Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liver Diseases Therapeutics Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Liver Diseases Therapeutics Drugs Company, Product Type & Application Table 13. Global Liver Diseases Therapeutics Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liver Diseases Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Liver Diseases Therapeutics Drugs Table 18. Significant Companies of Injection Liver Diseases Therapeutics Drugs Table 19. Global Liver Diseases Therapeutics Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Liver Diseases Therapeutics Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Liver Diseases Therapeutics Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Liver Diseases Therapeutics Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liver Diseases Therapeutics Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Liver Diseases Therapeutics Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Liver Diseases Therapeutics Drugs Sales Value Share by Type (2021-2026) Table 28. Global Liver Diseases Therapeutics Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Other Table 32. Global Liver Diseases Therapeutics Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Liver Diseases Therapeutics Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Liver Diseases Therapeutics Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Liver Diseases Therapeutics Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Liver Diseases Therapeutics Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Liver Diseases Therapeutics Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Liver Diseases Therapeutics Drugs Sales Value Share by Application (2021-2026) Table 41. Global Liver Diseases Therapeutics Drugs Sales Value Share by Application (2027-2032) Table 42. Global Liver Diseases Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Liver Diseases Therapeutics Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Liver Diseases Therapeutics Drugs Sales Market Share by Region (2021-2026) Table 45. Global Liver Diseases Therapeutics Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Liver Diseases Therapeutics Drugs Sales Market Share by Region (2027-2032) Table 47. Global Liver Diseases Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Liver Diseases Therapeutics Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Liver Diseases Therapeutics Drugs Sales Value Share by Region (2021-2026) Table 50. Global Liver Diseases Therapeutics Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Liver Diseases Therapeutics Drugs Sales Value Share by Region (2027-2032) Table 52. Global Liver Diseases Therapeutics Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Liver Diseases Therapeutics Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Liver Diseases Therapeutics Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Liver Diseases Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Liver Diseases Therapeutics Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global Liver Diseases Therapeutics Drugs Sales Market Share by Country (2021-2026) Table 58. Global Liver Diseases Therapeutics Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Liver Diseases Therapeutics Drugs Sales Market Share by Country (2027-2032) Table 60. Global Liver Diseases Therapeutics Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Liver Diseases Therapeutics Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Liver Diseases Therapeutics Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Liver Diseases Therapeutics Drugs Sales Value Market Share by Country (2027-2032) Table 64. Achillion Pharmaceuticals Company Information Table 65. Achillion Pharmaceuticals Business Overview Table 66. Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio Table 68. Achillion Pharmaceuticals Recent Development Table 69. Angion Biomedica Company Information Table 70. Angion Biomedica Business Overview Table 71. Angion Biomedica Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Angion Biomedica Liver Diseases Therapeutics Drugs Product Portfolio Table 73. Angion Biomedica Recent Development Table 74. F. Hoffmann-La Roche Company Information Table 75. F. Hoffmann-La Roche Business Overview Table 76. F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Product Portfolio Table 78. F. Hoffmann-La Roche Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Gilead Sciences Liver Diseases Therapeutics Drugs Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. LG Life Sciences Company Information Table 85. LG Life Sciences Business Overview Table 86. LG Life Sciences Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. LG Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio Table 88. LG Life Sciences Recent Development Table 89. Phenex Pharmaceuticals Company Information Table 90. Phenex Pharmaceuticals Business Overview Table 91. Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio Table 93. Phenex Pharmaceuticals Recent Development Table 94. ProMetic Life Sciences Company Information Table 95. ProMetic Life Sciences Business Overview Table 96. ProMetic Life Sciences Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ProMetic Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio Table 98. ProMetic Life Sciences Recent Development Table 99. Raptor Pharmaceuticals Company Information Table 100. Raptor Pharmaceuticals Business Overview Table 101. Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio Table 103. Raptor Pharmaceuticals Recent Development Table 104. Verva Pharmaceuticals Company Information Table 105. Verva Pharmaceuticals Business Overview Table 106. Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio Table 108. Verva Pharmaceuticals Recent Development Table 109. AbbVie Company Information Table 110. AbbVie Business Overview Table 111. AbbVie Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. AbbVie Liver Diseases Therapeutics Drugs Product Portfolio Table 113. AbbVie Recent Development Table 114. Bayer Company Information Table 115. Bayer Business Overview Table 116. Bayer Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Bayer Liver Diseases Therapeutics Drugs Product Portfolio Table 118. Bayer Recent Development Table 119. GlaxoSmithKline Company Information Table 120. GlaxoSmithKline Business Overview Table 121. GlaxoSmithKline Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. GlaxoSmithKline Liver Diseases Therapeutics Drugs Product Portfolio Table 123. GlaxoSmithKline Recent Development Table 124. Merck Company Information Table 125. Merck Business Overview Table 126. Merck Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Merck Liver Diseases Therapeutics Drugs Product Portfolio Table 128. Merck Recent Development Table 129. Johnson & Johnson Company Information Table 130. Johnson & Johnson Business Overview Table 131. Johnson & Johnson Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Johnson & Johnson Liver Diseases Therapeutics Drugs Product Portfolio Table 133. Johnson & Johnson Recent Development Table 134. Shenzhen Kangtai Biological Products Company Information Table 135. Shenzhen Kangtai Biological Products Business Overview Table 136. Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Product Portfolio Table 138. Shenzhen Kangtai Biological Products Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Liver Diseases Therapeutics Drugs Distributors List Table 142. Liver Diseases Therapeutics Drugs Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Liver Diseases Therapeutics Drugs Product Image Figure 2. Global Liver Diseases Therapeutics Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liver Diseases Therapeutics Drugs Sales (2021-2032) & (K Units) Figure 5. Global Liver Diseases Therapeutics Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Liver Diseases Therapeutics Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Liver Diseases Therapeutics Drugs Image Figure 10. Injection Liver Diseases Therapeutics Drugs Image Figure 11. Global Liver Diseases Therapeutics Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Liver Diseases Therapeutics Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Liver Diseases Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liver Diseases Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liver Diseases Therapeutics Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Other Image Figure 20. Global Liver Diseases Therapeutics Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Liver Diseases Therapeutics Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Liver Diseases Therapeutics Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Liver Diseases Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Liver Diseases Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Liver Diseases Therapeutics Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Liver Diseases Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Liver Diseases Therapeutics Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Liver Diseases Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Liver Diseases Therapeutics Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Liver Diseases Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Liver Diseases Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Liver Diseases Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Liver Diseases Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Liver Diseases Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Liver Diseases Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Liver Diseases Therapeutics Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Liver Diseases Therapeutics Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Liver Diseases Therapeutics Drugs
  • Injection Liver Diseases Therapeutics Drugs
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Achillion Pharmaceuticals
  • Angion Biomedica
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • LG Life Sciences
  • Phenex Pharmaceuticals
  • ProMetic Life Sciences
  • Raptor Pharmaceuticals
  • Verva Pharmaceuticals
  • AbbVie
  • Bayer
  • GlaxoSmithKline
  • Merck
  • Johnson & Johnson
  • Shenzhen Kangtai Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Liver Diseases Therapeutics Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Liver Diseases Therapeutics Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liver Diseases Therapeutics Drugs Market Dynamics
  1. 2.1 Liver Diseases Therapeutics Drugs Industry Trends
  2. 2.2 Liver Diseases Therapeutics Drugs Industry Drivers
  3. 2.3 Liver Diseases Therapeutics Drugs Industry Opportunities and Challenges
  4. 2.4 Liver Diseases Therapeutics Drugs Industry Restraints
3 Liver Diseases Therapeutics Drugs Market by Company
  1. 3.1 Global Liver Diseases Therapeutics Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Liver Diseases Therapeutics Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Liver Diseases Therapeutics Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Liver Diseases Therapeutics Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Liver Diseases Therapeutics Drugs Company Ranking (2024-2026)
  6. 3.6 Global Liver Diseases Therapeutics Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Liver Diseases Therapeutics Drugs Company Product Type and Application
  8. 3.8 Global Liver Diseases Therapeutics Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liver Diseases Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liver Diseases Therapeutics Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liver Diseases Therapeutics Drugs Market by Type
  1. 4.1 Liver Diseases Therapeutics Drugs Type Introduction
  2. 4.1.1 Oral Liver Diseases Therapeutics Drugs
  3. 4.1.2 Injection Liver Diseases Therapeutics Drugs
  4. 4.2 Global Liver Diseases Therapeutics Drugs Sales Volume by Type
  5. 4.2.1 Global Liver Diseases Therapeutics Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liver Diseases Therapeutics Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Liver Diseases Therapeutics Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Liver Diseases Therapeutics Drugs Sales Value by Type
  9. 4.3.1 Global Liver Diseases Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Liver Diseases Therapeutics Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Liver Diseases Therapeutics Drugs Sales Value Share by Type (2021-2032)
5 Liver Diseases Therapeutics Drugs Market by Application
  1. 5.1 Liver Diseases Therapeutics Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Liver Diseases Therapeutics Drugs Sales Volume by Application
  6. 5.2.1 Global Liver Diseases Therapeutics Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liver Diseases Therapeutics Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Liver Diseases Therapeutics Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Liver Diseases Therapeutics Drugs Sales Value by Application
  10. 5.3.1 Global Liver Diseases Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liver Diseases Therapeutics Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Liver Diseases Therapeutics Drugs Sales Value Share by Application (2021-2032)
6 Liver Diseases Therapeutics Drugs Regional Sales and Value Analysis
  1. 6.1 Global Liver Diseases Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liver Diseases Therapeutics Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Liver Diseases Therapeutics Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Liver Diseases Therapeutics Drugs Sales by Region (2027-2032)
  5. 6.3 Global Liver Diseases Therapeutics Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liver Diseases Therapeutics Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liver Diseases Therapeutics Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liver Diseases Therapeutics Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Liver Diseases Therapeutics Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Liver Diseases Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Liver Diseases Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liver Diseases Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Liver Diseases Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liver Diseases Therapeutics Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liver Diseases Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
7 Liver Diseases Therapeutics Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Liver Diseases Therapeutics Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liver Diseases Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Liver Diseases Therapeutics Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Liver Diseases Therapeutics Drugs Sales by Country (2027-2032)
  6. 7.4 Global Liver Diseases Therapeutics Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liver Diseases Therapeutics Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liver Diseases Therapeutics Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liver Diseases Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liver Diseases Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liver Diseases Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Achillion Pharmaceuticals
  2. 8.1.1 Achillion Pharmaceuticals Company Information
  3. 8.1.2 Achillion Pharmaceuticals Business Overview
  4. 8.1.3 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
  6. 8.1.5 Achillion Pharmaceuticals Recent Developments
  7. 8.2 Angion Biomedica
  8. 8.2.1 Angion Biomedica Company Information
  9. 8.2.2 Angion Biomedica Business Overview
  10. 8.2.3 Angion Biomedica Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Angion Biomedica Liver Diseases Therapeutics Drugs Product Portfolio
  12. 8.2.5 Angion Biomedica Recent Developments
  13. 8.3 F. Hoffmann-La Roche
  14. 8.3.1 F. Hoffmann-La Roche Company Information
  15. 8.3.2 F. Hoffmann-La Roche Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Liver Diseases Therapeutics Drugs Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 LG Life Sciences
  26. 8.5.1 LG Life Sciences Company Information
  27. 8.5.2 LG Life Sciences Business Overview
  28. 8.5.3 LG Life Sciences Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 LG Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
  30. 8.5.5 LG Life Sciences Recent Developments
  31. 8.6 Phenex Pharmaceuticals
  32. 8.6.1 Phenex Pharmaceuticals Company Information
  33. 8.6.2 Phenex Pharmaceuticals Business Overview
  34. 8.6.3 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
  36. 8.6.5 Phenex Pharmaceuticals Recent Developments
  37. 8.7 ProMetic Life Sciences
  38. 8.7.1 ProMetic Life Sciences Company Information
  39. 8.7.2 ProMetic Life Sciences Business Overview
  40. 8.7.3 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
  42. 8.7.5 ProMetic Life Sciences Recent Developments
  43. 8.8 Raptor Pharmaceuticals
  44. 8.8.1 Raptor Pharmaceuticals Company Information
  45. 8.8.2 Raptor Pharmaceuticals Business Overview
  46. 8.8.3 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
  48. 8.8.5 Raptor Pharmaceuticals Recent Developments
  49. 8.9 Verva Pharmaceuticals
  50. 8.9.1 Verva Pharmaceuticals Company Information
  51. 8.9.2 Verva Pharmaceuticals Business Overview
  52. 8.9.3 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
  54. 8.9.5 Verva Pharmaceuticals Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Liver Diseases Therapeutics Drugs Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Liver Diseases Therapeutics Drugs Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Liver Diseases Therapeutics Drugs Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck Liver Diseases Therapeutics Drugs Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Johnson & Johnson
  80. 8.14.1 Johnson & Johnson Company Information
  81. 8.14.2 Johnson & Johnson Business Overview
  82. 8.14.3 Johnson & Johnson Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Johnson & Johnson Liver Diseases Therapeutics Drugs Product Portfolio
  84. 8.14.5 Johnson & Johnson Recent Developments
  85. 8.15 Shenzhen Kangtai Biological Products
  86. 8.15.1 Shenzhen Kangtai Biological Products Company Information
  87. 8.15.2 Shenzhen Kangtai Biological Products Business Overview
  88. 8.15.3 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Product Portfolio
  90. 8.15.5 Shenzhen Kangtai Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liver Diseases Therapeutics Drugs Value Chain Analysis
  2. 9.1.1 Liver Diseases Therapeutics Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liver Diseases Therapeutics Drugs Sales Mode & Process
  6. 9.2 Liver Diseases Therapeutics Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liver Diseases Therapeutics Drugs Distributors
  9. 9.2.3 Liver Diseases Therapeutics Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst